Enlivex Therapeutics (ENLV) to Release Quarterly Earnings on Monday

Key Points

• Enlivex will release Q4 2025 results before the market opens on Monday, March 30, 2026, and analysts expect EPS of ($0.03) per share; an earnings call is scheduled for 4:00 PM ET that day.
• Shares fell 5.6%, opened at $1.02, trade in a 12‑month range of $0.66–$2.10, and the company has a market cap of $242.1 million.
• Brokerage ratings are mixed with a MarketBeat consensus of Hold and an average price target of $13.00, while institutional ownership remains low at 1.02% despite several firms recently increasing positions.

Enlivex Therapeutics (NASDAQ:ENLV - Get Free Report) is expected to release its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect Enlivex Therapeutics to post earnings of ($0.03) per share for the quarter. Interested persons can check the company's upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Monday, March 30, 2026 at 4:00 PM ET.

Enlivex Therapeutics Stock Down 5.6%

Shares of Enlivex Therapeutics stock opened at $1.02 on Monday. Enlivex Therapeutics has a twelve month low of $0.66 and a twelve month high of $2.10. The business has a 50-day moving average price of $1.08 and a 200-day moving average price of $1.02. The firm has a market cap of $242.13 million, a price-to-earnings ratio of -1.85 and a beta of 1.55.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ENLV. Jane Street Group LLC increased its stake in Enlivex Therapeutics by 527.4% during the first quarter. Jane Street Group LLC now owns 80,759 shares of the company's stock worth $78,000 after acquiring an additional 67,886 shares during the last quarter. Susquehanna International Group LLP bought a new stake in shares of Enlivex Therapeutics in the 3rd quarter valued at approximately $57,000. Renaissance Technologies LLC lifted its stake in shares of Enlivex Therapeutics by 99.4% in the 4th quarter. Renaissance Technologies LLC now owns 313,628 shares of the company's stock valued at $221,000 after purchasing an additional 156,336 shares during the last quarter. HRT Financial LP boosted its holdings in shares of Enlivex Therapeutics by 719.4% in the 4th quarter. HRT Financial LP now owns 153,990 shares of the company's stock worth $108,000 after purchasing an additional 135,198 shares during the period. Finally, XTX Topco Ltd boosted its holdings in shares of Enlivex Therapeutics by 44.8% in the 4th quarter. XTX Topco Ltd now owns 61,800 shares of the company's stock worth $43,000 after purchasing an additional 19,132 shares during the period. Institutional investors own 1.02% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently commented on ENLV. D. Boral Capital reissued a "hold" rating on shares of Enlivex Therapeutics in a research note on Monday, November 24th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Enlivex Therapeutics in a research note on Monday, December 29th. HC Wainwright upped their price objective on Enlivex Therapeutics from $7.00 to $13.00 and gave the stock a "buy" rating in a report on Monday, January 12th. Finally, Wall Street Zen upgraded Enlivex Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, February 28th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $13.00.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company's lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.